Navigation Links
Worldwide Clinical Trials Emerges as Leading Global Contract Research Organization
Date:7/9/2008

- Provides expertise in high-growth therapeutic areas to pharmaceutical and

biotechnology companies

- Aggressive acquisition strategy over the last year

BEVERLY HILLS, Calif., July 9 /PRNewswire/ -- Worldwide Clinical Trials, Inc.("WCT"), formed by Dr. Neal R. Cutler and a team of scientists, today reached a milestone in establishing itself as a premier global contract research organization with the announcement that it has closed the acquisition of MediQuest, a contract research organization providing specialized clinical development services to biopharmaceutical companies. The MediQuest acquisition was the most recent of five acquisitions made by WCT over the last year including Evidence Clinical and Pharmaceutical Research LLC, Clinical Studies Management Group, Inc., Nottingham Clinical Research Limited and CEDRA Corporation. The five acquisitions extend WCT's global footprint to more than 30 countries.

WCT is a leading therapeutically focused contract research organization that applies deep therapeutic expertise to help customers achieve their drug development goals. WCT provides clinical consulting and Phase I-IV drug development services -- including clinical trial design, clinical operations, data management, biostatistics, medical affairs, safety/pharmacovigilance, Electronic Data Capture and Interactive Voice Response System technologies, regulatory affairs, quality assurance bioanalytical services (LC-MS-MS, ligand binding, biomarkers), and pharmacokinetics -- for global pharma, specialty pharma and biotech companies.

Formed in 2007 by Dr. Cutler in partnership with The Jordan Company, a leading private equity firm, the company focuses on complex, high-growth therapeutic areas with primary expertise in central nervous system, and cardiovascular disease, along with significant experience in chronic inflammatory disease, metabolic / endocrinology and oncology. As expertise in these areas continues to be in demand, Worldwide Clinical Trials has sought to broaden its business through strategic growth and a highly selective acquisition strategy of companies that complements its existing skill-set.

"The acquisitions we have completed to date significantly enhance our contract research organization capabilities and our ability to manage large, global trials, within our primary therapeutic areas of focus. That in turn positions us well for future growth," said Dr. Cutler. "We have effectively expanded our operations and significantly enhanced our ability to meet the global needs of pharma and biotech companies. Our presence in Eastern Europe and Russia, two of the most attractive growth regions for clinical trials, helps transform our business into a truly global contract research organization."

Dr. Cutler and his team have reunited under the name of their former company, Worldwide Clinical Trials, which they founded in 1994 and sold to UnitedHealth in 1999. Dr. Cutler is known for pioneering several revolutionary techniques that increased the quality, safety and speed of drug development.

About Worldwide Clinical Trials, Inc.

Worldwide Clinical Trials (http://www.wwctrials.com) is a full-service contract research organization (CRO) that is medically and scientifically focused on central nervous system (CNS) and cardiovascular disease. WCT delivers quality clinical trials with leading edge science and medicine to help clients think through design, methodology and regulatory issues that are unique to every development program. WCT provides highly focused CRO services in all phases of research -- worldwide.

About The Jordan Company

The Jordan Company (http://www.thejordancompany.com), founded in 1982, is a leading middle-market private equity firm with over $6 billion of assets under management and a successful track record of investing in and growing businesses across a wide range of industries. The firm's partners have been investing together for more than two decades, establishing The Jordan Company as one of the most experienced and stable investment teams in private equity. The investment team is supported by the firm's Operations Management Group, which initiates and supports operational improvements in portfolio companies. The firm generates deal flow through a well-developed network of sourcing relationships. Headquartered in New York, The Jordan Company also has offices in Chicago and Shanghai.


'/>"/>
SOURCE Worldwide Clinical Trials, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Pfizer and Bristol-Myers Squibb Finalize Agreement for Worldwide Collaboration on Metabolic Disorders Program
2. Avicena Signs Worldwide Exclusive Distribution Agreement with RITA Corporation for its Proprietary Dermaceutical Compounds
3. Stereotaxis Niobe System Used to Perform More Than 10,000 Procedures Worldwide
4. Martek Signs Multi-Year Worldwide Sole Source Supply Agreement with Abbott
5. MultiCell Technologies Signs Worldwide Exclusive License Agreement With Corning Incorporated
6. AstraZeneca Bolsters Its Worldwide Biologics Division Through Integration of Cambridge Antibody Technology Into MedImmune
7. REMICADE(R) Becomes First Anti-TNF Biologic Therapy to Treat One Million Patients Worldwide
8. Co-Inventor of Amgens Aranesp(R) Technology Directs Worldwide Patent Strategy for Diffusion Pharmaceuticals First-in-Class Oxygen Enhancing Therapeutics
9. Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
10. Novo Nordisk Appoints Alan C. Moses as Chief Medical Officer Worldwide
11. Starion Achieves Worldwide Distribution of Proprietary Tissue Welding Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... ... February 21, 2017 , ... Vortex ... , a fully automated benchtop system for collecting intact circulating tumor cells (CTCs) ... at the Molecular Medicine Tri Conference (Tri-Con) Annual Meeting 2017 (February 19–24 San ...
(Date:2/21/2017)... ... 21, 2017 , ... The medical potential of stem cells is both extensive ... medicine, due to their differentiating characteristics. Stem cells are unique as the have the ... induced to become tissue or organic-specific cells with special functions. , Stem cell ...
(Date:2/21/2017)... ... 2017 , ... Creation Technologies, a private company and 25-year ... (OEMs) , today announced it has received the ‘Highest Overall Customer Rating’ Service ... category of electronics manufacturing services (EMS) providers with annual revenues over $500 million. ...
(Date:2/21/2017)... --  Logicalis Healthcare Solutions , the healthcare-focused practice within ... provider ( www.us.logicalis.com ), today announced a new service ... service will help hospital CIOs make the best use ... and other clinicians immediate access to a pool of ... hospital IT staff to focus on broader issues such ...
Breaking Biology Technology:
(Date:1/31/2017)... , Jan. 31, 2017  Spero Therapeutics, LLC, ... for the treatment of bacterial infections, today announced ... antibacterial candidates from Pro Bono Bio Ltd (PBB) ... of multi-drug resistant forms of Gram-negative bacteria.   The ... Infectives Ltd, a PBB group company. ...
(Date:1/26/2017)... Jan. 26, 2017  Acuity Market Intelligence today ... and Digital Identity".  Acuity characterizes 2017 as a ... increased adoption reflects a new understanding of the ... "Biometrics and digital identity are often perceived as ... Most , Principal of Acuity Market intelligence. "However, ...
(Date:1/24/2017)... 2017  It sounds simple and harmless—an electronic ... vital signs and alerts parents on their smart ... level drops. But pediatric experts argue that such ... no evidence of medical benefits, especially to healthy ... to parents of healthy babies, promising peace of ...
Breaking Biology News(10 mins):